clinical trial · NCT06963346
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute·phase1·suspended·n = 12
Bladder CancerRomidepsinDurvalumab
brief summary
In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
started
Jun 24, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Mar 9, 2026
official title
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol